PT  - JOURNAL ARTICLE
AU  - Zeng, Qiang
AU  - Yang, Xue
AU  - Gao, Qi
AU  - Lin, Biao-yang
AU  - Li, Yong-zhe
AU  - Huang, Gang
AU  - Xu, Yang
TI  - Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International Standard
AID  - 10.1101/2022.03.31.22273272
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.31.22273272
4099  - http://medrxiv.org/content/early/2022/04/01/2022.03.31.22273272.short
4100  - http://medrxiv.org/content/early/2022/04/01/2022.03.31.22273272.full
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with more than 485 millions infected. Questions about non-responders to SARS-CoV-2 vaccines remain unaddressed. Here, we report data from people after administering the complete dose of SARS-CoV-2 vaccines using the World Health Organization International Standard for anti-SARS-CoV-2 immunoglobulin. Our study showed that immune cells such as CD4 cells, CD8 cells, and B cells and anti-spike immunoglobulin G levels were significantly reduced in the elderly. There were 7.5% non-responders among the 18–59 yr group and 11.7% in the ≥60 yr group. A titer of anti-SARS-CoV-2 spike immunoglobulin G is blew 50 BAU/mL to be considered as non-responders at intervals of 30 to 90 days after the last vaccine dose. Booster vaccination may be recommended for non-responders to reduce the disease severity and mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the project of Antibody Immunity Evaluation after SARS-CoV-2 Vaccination in General Population (Z211100002521024) from Beijing Science and Technology Commission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Chinese PLA General Hospital gave ethical approval for this work (No. S2021-481-01)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript